InnoTherapy Inc (246960) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InnoTherapy Inc (246960) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-107.41 Million ≈ $-72.79K USD) by net assets (₩24.57 Billion ≈ $16.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
InnoTherapy Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read InnoTherapy Inc debt and liabilities for a breakdown of total debt and financial obligations.
InnoTherapy Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InnoTherapy Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kc Green Holdi
KO:009440
|
0.012x |
|
hGears AG
XETRA:HGEA
|
-0.050x |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
-0.003x |
|
EMC Public Company Limited
BK:EMC
|
0.209x |
|
Viet Phat Import Export Trading Investment JSC
VN:VPG
|
N/A |
|
Karnalyte Resources Inc.
TO:KRN
|
-0.060x |
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
0.004x |
|
NOWVERTICAL GROUP INC.
F:5XQ
|
-0.357x |
Annual Cash Flow Conversion Efficiency for InnoTherapy Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of InnoTherapy Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of InnoTherapy Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩15.52 Billion ≈ $10.52 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.384x | -157.47% |
| 2023-12-31 | ₩18.90 Billion ≈ $12.81 Million |
₩-2.82 Billion ≈ $-1.91 Million |
-0.149x | +52.60% |
| 2022-12-31 | ₩13.05 Billion ≈ $8.84 Million |
₩-4.10 Billion ≈ $-2.78 Million |
-0.315x | +20.39% |
| 2021-12-31 | ₩10.08 Billion ≈ $6.83 Million |
₩-3.98 Billion ≈ $-2.70 Million |
-0.395x | -78.14% |
| 2020-12-31 | ₩12.94 Billion ≈ $8.77 Million |
₩-2.87 Billion ≈ $-1.95 Million |
-0.222x | -2.53% |
| 2019-12-31 | ₩15.08 Billion ≈ $10.22 Million |
₩-3.26 Billion ≈ $-2.21 Million |
-0.216x | +5.49% |
| 2018-12-31 | ₩9.52 Billion ≈ $6.45 Million |
₩-2.18 Billion ≈ $-1.48 Million |
-0.229x | +68.62% |
| 2017-12-31 | ₩3.10 Billion ≈ $2.10 Million |
₩-2.26 Billion ≈ $-1.53 Million |
-0.730x | -294.88% |
| 2016-12-31 | ₩6.07 Billion ≈ $4.12 Million |
₩-1.12 Billion ≈ $-760.70K |
-0.185x | -200.06% |
| 2015-12-31 | ₩-6.23 Billion ≈ $-4.22 Million |
₩-1.15 Billion ≈ $-779.63K |
0.185x | -- |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more